Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
Key Highlights
- ➤Anteris (AVR) reported 1% heart-failure hospitalization at one year.
- ➤DurAVR maintained an 8.9 mmHg mean gradient and 2.2 cm² mean EOA.
- ➤DurAVR showed no moderate or severe PVL or valve-related deaths through one year.
- ➤97% of patients were free from moderate or severe PPM at 30 days.
- ➤PARADIGM will randomize approximately 1,000 patients against commercial TAVR valves. (AVR)
Expert Statements
Rishi Puri, Interventional Cardiologist, Cleveland Clinic
“Small aortic annuli are where we most often see elevated gradients and mismatch after TAVR, and these patients are disproportionately women. In this symptomatic cohort, DurAVR delivered single-digit gradients, no moderate or greater paravalvular leak and 97% freedom from moderate or severe mismatch at 30 days. While cross-trial comparisons should be interpreted with caution, what stands out to me is heart failure hospitalization of just 1% at one year. These patients had a mean STS score of 4.7%, and most were in NYHA class III or IV, yet 1% is well below the hospitalization rates reported in contemporary clinical trials with currently marketed products. These are encouraging results, and the randomized PARADIGM trial is the right next test.”
Chris Meduri, Chief Medical Officer of Anteris
“Small annuli are the hardest test in TAVR, and these patients were symptomatic, with 61% in NYHA class III or IV at baseline. At one year, heart failure hospitalization was just 1%, a fraction of the rate typically observed after valve replacement. Heart failure admissions are the event patients feel most, health systems pay for most and that most closely predicts mortality. The cardiac MRI data show why DurAVR is different: with single-digit gradients and no moderate or severe paravalvular leak, left ventricular mass regressed by 24%, which tells us the heart is unloading and beginning to remodel. We believe DurAVR's biomimetic design and its potential to restore more physiologic blood flow may contribute to improved cardiac remodeling. These findings are consistent with that hypothesis, and PARADIGM is designed to test DurAVR head-to-head against today's commercial valves. These results give us strong conviction going into the pivotal trial.”
Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris
“Reducing heart failure hospitalization is among the most consequential events after aortic valve replacement, due to its proven correlation with CV mortality. In a pooled analysis of more than 3,400 patients treated with TAVR or surgical aortic valve replacement in the PARTNER trials, the 1-year heart failure hospitalization rate was 6.7%, and these hospitalizations were associated with increased mortality. In the randomized SMART trial of small-annulus patients at lower predicted risk (mean STS-PROM 3.3%), 1-year heart failure hospitalization was 4.1% with the Evolut valve and 3.5% with the SAPIEN valve. Against this backdrop, our current dataset gives us great confidence for the ongoing pivotal PARADIGM study where cardiovascular hospitalization is also a component of the primary endpoint.”
MINNEAPOLIS and BRISBANE, Nov. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced 1-year clinical and hemodynamic outcomes for the DurAVR(®) Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli (annulus area 404 ± 37 mm(2)), the anatomy in which transcatheter valves most often leave patients with elevated gradients and prosthesis-patient mismatch(*) (PPM).
At 1 year, 1% of patients had been hospitalized for heart failure. DurAVR THV maintained a mean pressure gradient of 8.9 mmHg and a mean effective orifice area (EOA) of 2.2 cm(2), with no moderate or severe paravalvular leak (PVL) observed and no valve-related mortality reported. At 30 days, 97% of patients were free from moderate or severe PPM. Symptoms improved substantially: the proportion of patients who achieved New York Heart Association (NYHA) class I/II rose from 39% at baseline to 96% at 1 year.
Get started
Create a free account to read the full story.
